<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039477</url>
  </required_header>
  <id_info>
    <org_study_id>KZR-616-005</org_study_id>
    <nct_id>NCT04039477</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP</brief_title>
  <acronym>MARINA</acronym>
  <official_title>A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kezar Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kezar Life Sciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 randomized, dose-blind, multicenter study designed to evaluate the safety,&#xD;
      tolerability, efficacy, Pharmacokinetics (PK), and Pharmacodynamics (PD) of treatment with&#xD;
      KZR-616 in patients with active Autoimmune Hemolytic Anemia or Immune Thrombocytopenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Clinical trial activity slowdown due to COVID-19 pandemic, high screen fail rate, and lack of&#xD;
    enrollment led to the decision to withdraw the MARINA study.&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Actual">August 5, 2020</completion_date>
  <primary_completion_date type="Actual">August 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from Baseline to Week 13 in hematologic parameters of interest in evaluable patients (Hgb for AIHA; Platelets [PLT] for ITP)</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 13 in hematologic parameters of interest (Hgb for AIHA; PLT for ITP) in the intent to treat (ITT) population</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline over time in hematologic parameters of interest (Hgb for AIHA; PLT for ITP)</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a response at Week 13</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients over time with a response</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients over time with loss of response</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients over time with sustained response</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline over time in Hct</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline over time in Lactate Dehydrogenase (LDH)</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline over time in Patient Global Assessment scores</measure>
    <time_frame>Baseline and every 4 weeks for 25 weeks</time_frame>
    <description>The PtGA is a visual analog scale (VAS) ranging from 0 to 100. Patients will provide a global rating of their disease, for the day of the visit, in response to the statement &quot;Considering all the ways that your disease affects you, please rate how you are feeling today by clicking or tapping on the line:&quot; using a 100-point VAS where 0 is &quot;very good, no symptoms&quot; and 100 is &quot;very poor, very severe symptoms.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For AIHA: Proportion of patients with an Hgb &gt;12 g/dL or 2 g/dL higher than Baseline at W13</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For AIHA: Number of blood transfusions and units of blood administered over time</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For ITP: Number of platelet transfusions and units of platelets administered over time</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of KZR-616 in patients with AIHA or ITP as assessed by monitoring incidence and severity of adverse events (AEs)</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) following KZR-616 injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) following KZR-616 injection</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration (Tmax) following KZR-616 injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration (Tmax) following KZR-616 injection</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) following KZR-616 injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) following KZR-616 injection</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) following KZR-616 injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) following KZR-616 injection</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Arm A - KZR-616 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KZR-616 30mg Subcutaneous (SC) injection weekly for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - KZR-616 45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KZR-616 30 mg SC injection weekly for 1 dose then 45mg weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KZR-616</intervention_name>
    <description>Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks</description>
    <arm_group_label>Arm A - KZR-616 30mg</arm_group_label>
    <arm_group_label>Arm B - KZR-616 45mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients must be at least 18 years of age at the time of signing informed&#xD;
             consent at Screening&#xD;
&#xD;
          2. Body Mass Index (BMI) equal to or greater than 18 kg/m2&#xD;
&#xD;
          3. Have a documented diagnosis of primary or secondary AIHA, ITP, or primary Evans&#xD;
             syndrome&#xD;
&#xD;
          4. AIHA or ITP disease activity as follows::&#xD;
&#xD;
               1. ITP: Per central or local laboratory assessments on 2 separate occasions ≥7 days&#xD;
                  apart during Screening, a mean Platelet (PLT) ≤30×109/L with no individual PLT&#xD;
                  &gt;35×109/L; or for those patients receiving a constant dose of permitted&#xD;
                  treatments for ITP: a mean PLT &lt;50×109/L, with no count &gt;55×109/L&#xD;
&#xD;
               2. AIHA: Hgb ≤10 g/dL and presence of any 2 of the following:&#xD;
&#xD;
             i. Haptoglobin &lt;lower limit of normal (LLN) ii. Corrected reticulocyte count &gt;upper&#xD;
             limit of normal (ULN) iii. LDH &gt;ULN iv. Indirect bilirubin &gt;ULN.&#xD;
&#xD;
          5. Documented inadequate response on intolerance to ≥1 standard treatment approach for&#xD;
             AIHA or ≥2 standard treatment approaches for ITP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systemic Lupus Erythematosus (SLE) with confirmed anti-phospholipid antibody syndrome,&#xD;
             the presence of positive lupus anti-coagulant test, moderate-high titer&#xD;
             anti-cardiolipin IgG or IgM or moderate-high titer anti-beta2-globuilin IgG or IgM or&#xD;
             severe central nervous system involvement&#xD;
&#xD;
          2. History of clinically significant coagulopathy, hereditary thrombocytopenia, anemia,&#xD;
             or family history of thrombocytopenia&#xD;
&#xD;
          3. History of primary immunodeficiency&#xD;
&#xD;
          4. Use of nonpermitted medications within the specified washout periods prior to&#xD;
             screening&#xD;
&#xD;
          5. Recent serious or ongoing infection, or risk for serious infection&#xD;
&#xD;
          6. Any of the following laboratory values at Screening:&#xD;
&#xD;
               1. Estimated glomerular filtration rate (eGFR) &lt;45 ml/min&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) &lt;1.5×109/L (1500/mm3)&#xD;
&#xD;
               3. Serum aspartate transaminase (AST), serum alanine transaminase (ALT) or serum&#xD;
                  alkaline phosphatase &gt;2.5×ULN&#xD;
&#xD;
               4. Thyroid stimulating hormone if outside of the central laboratory normal range and&#xD;
                  considered clinically significant&#xD;
&#xD;
               5. International normalized ratio (INR) or activated partial thromboplastin time&#xD;
                  (aPTT) &gt;1.5×ULN&#xD;
&#xD;
               6. Immunoglobulin G (IgG) &lt;500 mg/dL&#xD;
&#xD;
               7. For ITP patients only: total bilirubin &gt;1.5×ULN (3×ULN for patients with&#xD;
                  documented Gilbert's syndrome).&#xD;
&#xD;
          7. Presence of New York Heart Association Class III or IV heart failure, or uncontrolled&#xD;
             blood pressure, or prolonged QT interval&#xD;
&#xD;
          8. Major surgery within 12 weeks before Screening or planned during the study period&#xD;
&#xD;
          9. History of any thrombotic or embolic event within 12 months prior to Screening&#xD;
&#xD;
         10. Clinical evidence of significant unstable or uncontrolled diseases&#xD;
&#xD;
         11. Any active or suspected malignancy or history of documented malignancy within the last&#xD;
             5 years before Screening, except appropriately excised and cured cervical carcinoma in&#xD;
             situ or basal or squamous cell carcinoma of the skin, or non-muscle invasive bladder&#xD;
             cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kezar</last_name>
    <role>Study Director</role>
    <affiliation>Kezar Life Sciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR-616 Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune</keyword>
  <keyword>Hemolytic</keyword>
  <keyword>Anemia</keyword>
  <keyword>Autoimmune Hemolytic Anemia</keyword>
  <keyword>AIHA</keyword>
  <keyword>Immune</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Immune Thrombocytopenia</keyword>
  <keyword>ITP</keyword>
  <keyword>Blood disorders</keyword>
  <keyword>Hematology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

